Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 10-Q, filed Aug 13, 2026
- Incorporated
- Delaware
- Filings on record
- 62 filings
- On EDGAR
- CIK 2035832
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
Financials 3
News 5
Prospectuses and Registrations 5
Ownership 8 of 40
- 4 Insider reported a trade Sep 24, 2026
- 144 Notice of a proposed sale of restricted stock Sep 23, 2026
- 4 Insider reported a trade Jul 21, 2026
- 4 Insider reported a trade Jul 20, 2026
- 144 Notice of a proposed sale of restricted stock Jul 20, 2026
- 144 Notice of a proposed sale of restricted stock Jul 17, 2026
- 4 Insider reported a trade Jul 10, 2026
- 4 Insider reported a trade Jul 10, 2026
Other 8 of 9
- EFFECT Notice that a registration became effective Jan 8, 2026
- CERT Exchange certified a listing Jan 8, 2026
- 8-A12B Registration of a security for exchange listing Jan 7, 2026
- DRS/A Draft registration statement, submitted confidentially, amended Nov 14, 2025
- DRS/A Draft registration statement, submitted confidentially, amended May 22, 2025
- DRS/A Draft registration statement, submitted confidentially, amended Dec 13, 2024
- DRS/A Draft registration statement, submitted confidentially, amended Nov 22, 2024
- DRS Draft registration statement, submitted confidentially Oct 11, 2024
Everything here comes from Aktis Oncology, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.